2012
DOI: 10.4161/mabs.4.1.18543
|View full text |Cite
|
Sign up to set email alerts
|

Subcutaneous bioavailability of therapeutic antibodies as a function 
of FcRn binding affinity in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
68
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 65 publications
(73 citation statements)
references
References 26 publications
5
68
0
Order By: Relevance
“…57 Likewise, the N434Y variant has increased binding to murine FcRn at both pH6.0 and 7.4 resulting in comparable half-life to the IgG-WT in mice. 58 Nevertheless, we show in this study that several variants including this mutation N434Y result in half-life extension in hFcRn mice, emphasizing the limitations of using wild-type mice as preclinical models for the analysis of engineered mAbs.…”
Section: Discussionmentioning
confidence: 68%
“…57 Likewise, the N434Y variant has increased binding to murine FcRn at both pH6.0 and 7.4 resulting in comparable half-life to the IgG-WT in mice. 58 Nevertheless, we show in this study that several variants including this mutation N434Y result in half-life extension in hFcRn mice, emphasizing the limitations of using wild-type mice as preclinical models for the analysis of engineered mAbs.…”
Section: Discussionmentioning
confidence: 68%
“…For example, the s.c. bioavailability of 7E3 IgG1 was 3-fold higher in wild-type compared with FcRn-deficient mice (Wang et al, 2008). Increased affinity of mAbs to FcRn at pH 6.0 was associated with greater s.c. bioavailability, whereas an increased affinity at pH 7.4 led to a decrease in s.c. absorption in mice (Deng et al, 2010(Deng et al, , 2012. In contrast, no definitive effect of altering FcRn affinity on s.c. bioavailability was found for a series of IgG4 variants in cynomolgus monkeys (Datta-Mannan et al, 2012).…”
Section: Introductionmentioning
confidence: 79%
“…Recirculation of mAbs and transcytosis through FcRn are important mechanisms of mAb stabilization in vivo and distribution across tissues, respectively. [28][29][30] Thus, Fc modifications aimed at improving bioavailability and/or stability of therapeutic mAbs in vivo are being actively sought by several groups, even though a considerable amount of work is still required to define the best strategies and translate the laboratory findings into the clinic. Indeed, improved binding at acid pH does not necessarily translate into longer half-life and better bioavailability.…”
Section: Rtx Pdmentioning
confidence: 99%
“…Indeed, improved binding at acid pH does not necessarily translate into longer half-life and better bioavailability. 29,30 Finally, RTX can bind to C1q and activate the classical complement cascade. C1q is a protein complex composed of 18 peptides that form 6 identical globular heads on a single stem structure (often compared with a bunch of tulips).…”
Section: Rtx Pdmentioning
confidence: 99%
See 1 more Smart Citation